Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Small ; 13(3)2017 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-27775872

RESUMO

Inflammation has been reported as one significant hallmark of breast cancer in relation to tumor development, metastasis, and invasion. The bradykinin receptor 1 (B1R) is highly expressed on inflammatory breast tumor cells thus providing a promising targeting site for tumor recognition and sufficient receptor mediated endocytosis. In this study, the authors evaluate the targeting efficiency of l-form and d-form [des-Arg10 ]kallidin both in vitro and in vivo. To further improve the drug delivery efficiency, the authors establish a dandelion like nanoparticle by combining the polymeric drug conjugates and aptamer complex together. The doxorubicin conjugated polymer is complexed with adenosine-5'-triphosphate (ATP) sensitive hybridized aptamer in self-assembly process by intercalating into the double strand scaffolds. The acid labile conjugating bond and ATP sensitive aptamer endow the nanoparticle with dual responsiveness to intracellular milieu, thus triggering a quick drug release in tumor cells. Remarkable therapeutic effects and tuned in vivo pharmacokinetics profiles are shown by the aptamer complexed drug conjugates nanoparticle with B1R active targeting modification. Therefore the strategies of B1R targeting and ATP/pH dual-responsiveness nanoparticle help achieve enhanced drug accumulation within tumor cells and efficient chemotherapy for breast cancer.


Assuntos
Trifosfato de Adenosina/química , Sistemas de Liberação de Medicamentos , Calidina/análogos & derivados , Nanopartículas/química , Animais , Antineoplásicos/farmacologia , Linhagem Celular Tumoral , Doxorrubicina/farmacocinética , Doxorrubicina/farmacologia , Doxorrubicina/uso terapêutico , Liberação Controlada de Fármacos , Endocitose , Feminino , Concentração de Íons de Hidrogênio , Calidina/uso terapêutico , Masculino , Neoplasias Mamárias Animais/tratamento farmacológico , Neoplasias Mamárias Animais/patologia , Camundongos Nus , Nanopartículas/ultraestrutura , Polímeros/química , Ratos Sprague-Dawley , Distribuição Tecidual , Resultado do Tratamento , Carga Tumoral/efeitos dos fármacos , Ensaios Antitumorais Modelo de Xenoenxerto
3.
Immunopharmacology ; 36(2-3): 173-7, 1997 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9228543

RESUMO

Previous experiments in anesthetized pigs have demonstrated that blockade of the bradykinin B2 receptor in experimental endotoxin shock attenuates LPS-induced organ failure, lung dysfunction and mortality. Additional B1 receptor blockade in this situation seems to counteract the beneficial effects of B2 blockade. This suggests that the upregulation of B1 receptors during porcine LPS shock may be a useful mechanism of host defense. Furthermore, infusion of a B1 agonist during septic shock may be of therapeutic benefit. In order to prepare an experiment with B1 stimulation in LPS shock, we conducted a study in anesthetized pigs, in which the B1 receptor has been upregulated by infusion of bacterial lipopolysaccharide (LPS), by evaluating the effect of constant intravenous infusions of the B1 agonist des-Arg10-kallidin on the hypotensive response to bolus doses of this agonist. Following infusions of lipopolysaccharide from S. abortus equi, anesthetised pigs received repeated intra-arterial bolus injections of des-Arg10-kallidin before and during continuous infusions of this agonist in doses of 3, 10, 30 and 100 ng/kg/min. We found that all doses greater than 3 ng/kg/min produced attenuation of the hypotensive response produced by bolus administration of the B1 agonist des-Arg10-kallidin. We conclude that tachyphylaxis is an important feature to be considered in experiments with continuous administration of a B1 agonist in LPS shock.


Assuntos
Pressão Sanguínea/efeitos dos fármacos , Calidina/análogos & derivados , Receptores da Bradicinina/fisiologia , Choque Séptico/metabolismo , Taquifilaxia/fisiologia , Animais , Antagonistas dos Receptores da Bradicinina , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Interações Medicamentosas , Infusões Intravenosas , Injeções Intra-Arteriais , Calidina/administração & dosagem , Calidina/farmacologia , Calidina/uso terapêutico , Lipopolissacarídeos/toxicidade , Receptor B1 da Bradicinina , Receptores da Bradicinina/agonistas , Choque Séptico/induzido quimicamente , Choque Séptico/tratamento farmacológico , Suínos , Regulação para Cima
4.
Prog Clin Biol Res ; 308: 983-7, 1989.
Artigo em Inglês | MEDLINE | ID: mdl-2675079

RESUMO

The selective competitive bradykinin (BK) antagonist (B4148) produced significant inhibition of the hypotensive effect of BK in rats. Using a rat model of endotoxin shock, the fall in mean arterial blood pressure to an intravenous injection of lipopolysaccharide from E. coli was significantly attenuated by the B4148 as compared to controls. These findings suggest that kinins are involved in the hypotensive response to endotoxin shock in rats. The development of potent BK antagonists offers a new experimental approach for evaluating the role of kinins in this and other disease states.


Assuntos
Bradicinina/antagonistas & inibidores , Hipotensão/prevenção & controle , Calidina/análogos & derivados , Choque Séptico/complicações , Animais , Escherichia coli , Hipotensão/etiologia , Calidina/uso terapêutico , Cinética , Lipopolissacarídeos , Masculino , Ratos , Ratos Endogâmicos , Choque Séptico/tratamento farmacológico , Choque Séptico/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...